Cyteir Therapeutics, Inc. – NASDAQ:CYT
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Cyteir Therapeutics stock price monthly change
-2.59%
month
Cyteir Therapeutics stock price quarterly change
-0.33%
quarter
Cyteir Therapeutics stock price yearly change
+65.39%
year
Cyteir Therapeutics key metrics
Market Cap | 108.71M |
Enterprise value | N/A |
P/E | -1.34 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.44 |
PEG ratio | -0.03 |
EPS | -0.86 |
Revenue | N/A |
EBITDA | -37.42M |
Income | -30.88M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCyteir Therapeutics stock price history
Cyteir Therapeutics stock forecast
Cyteir Therapeutics financial statements
| Dec 2022 | 0 | -7.39M | |
|---|---|---|---|
| Mar 2023 | 0 | -11.55M | |
| Jun 2023 | 0 | -8.40M | |
| Sep 2023 | 0 | -3.53M |
| 2025 | 0 | -23.49M |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-05-10 | -0.27 | -0.35 |
|---|---|---|
| 2023-08-07 | -0.32 | -0.24 |
| 2024-03-28 | -0.2 | -0.25 |
| Dec 2022 | 153232000 | 6.94M | 4.53% |
|---|---|---|---|
| Mar 2023 | 138976000 | 4M | 2.88% |
| Jun 2023 | 134388000 | 6.60M | 4.91% |
| Sep 2023 | 131009000 | 5.97M | 4.56% |
| Dec 2022 | -6.91M | -302K | 147K |
|---|---|---|---|
| Mar 2023 | -10.16M | 150K | 103K |
| Jun 2023 | -4.14M | 153K | 428K |
| Sep 2023 | -4.55M | 0 | 164K |
Cyteir Therapeutics alternative data
| Aug 2023 | 46 |
|---|---|
| Sep 2023 | 46 |
| Oct 2023 | 46 |
| Nov 2023 | 46 |
| Dec 2023 | 46 |
| Jan 2024 | 46 |
| Feb 2024 | 46 |
| Mar 2024 | 46 |
| Apr 2024 | 46 |
| May 2024 | 46 |
| Jun 2024 | 46 |
| Jul 2024 | 46 |
Cyteir Therapeutics other data
23.84%
-34.00%
of CYT is owned by hedge funds
13
-17
8.40M
-12.02M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 277777 |
| Jul 2023 | 0 | 140500 |
| Mar 2024 | 284366 | 0 |
| Quarter | Transcript |
|---|---|
| Q4 2021 16 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Markus F. Renschler M.D. (1961) Pres, Chief Executive Officer & Director | $630,000 |
Mr. Andrew W. Gengos (1964) Chief Bus. Officer | $436,510 |
Dr. Paul Secrist Ph.D. (1966) Chief Scientific Officer | $265,230 |
| Mr. Joseph S. Zakrzewski (1962) Independent Investor & Chairman | $60,050 |
-
When is Cyteir Therapeutics's next earnings date?
Unfortunately, Cyteir Therapeutics's (CYT) next earnings date is currently unknown.
-
Does Cyteir Therapeutics pay dividends?
No, Cyteir Therapeutics does not pay dividends.
-
How much money does Cyteir Therapeutics make?
Cyteir Therapeutics has a market capitalization of 108.71M. Cyteir Therapeutics made a loss 43.95M US dollars in net income (profit) last year or -$0.25 on an earnings per share basis.
-
What is Cyteir Therapeutics's stock symbol?
Cyteir Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CYT".
-
What is Cyteir Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cyteir Therapeutics?
Shares of Cyteir Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cyteir Therapeutics's key executives?
Cyteir Therapeutics's management team includes the following people:
- Dr. Markus F. Renschler M.D. Pres, Chief Executive Officer & Director(age: 64, pay: $630,000)
- Mr. Andrew W. Gengos Chief Bus. Officer(age: 61, pay: $436,510)
- Dr. Paul Secrist Ph.D. Chief Scientific Officer(age: 59, pay: $265,230)
- Mr. Joseph S. Zakrzewski Independent Investor & Chairman(age: 63, pay: $60,050)
-
How many employees does Cyteir Therapeutics have?
As Jul 2024, Cyteir Therapeutics employs 46 workers.
-
When Cyteir Therapeutics went public?
Cyteir Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 18 Jun 2021.
-
What is Cyteir Therapeutics's official website?
The official website for Cyteir Therapeutics is cyteir.com.
-
Where are Cyteir Therapeutics's headquarters?
Cyteir Therapeutics is headquartered at 128 Spring Street, Lexington, MA.
-
How can i contact Cyteir Therapeutics?
Cyteir Therapeutics's mailing address is 128 Spring Street, Lexington, MA and company can be reached via phone at 857 285 4140.
Cyteir Therapeutics company profile:
Cyteir Therapeutics, Inc.
cyteir.comExchange:
NASDAQ
Full time employees:
46
Industry:
Biotechnology
Sector:
Healthcare
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
128 Spring Street
Lexington, MA 02421
Lexington, MA 02421
CIK: 0001662244
ISIN: US23284P1030
CUSIP: 550241103
